Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
View/ Open
Publication Date
2018-04Author
Arce Vargas, F
Furness, AJS
Litchfield, K
Joshi, K
Rosenthal, R
Ghorani, E
Solomon, I
Lesko, MH
Ruef, N
Roddie, C
Henry, JY
Spain, L
Ben Aissa, A
Georgiou, A
Wong, YNS
Smith, M
Strauss, D
Hayes, A
Nicol, D
O'Brien, T
Mårtensson, L
Ljungars, A
Teige, I
Frendéus, B
TRACERx Melanoma
TRACERx Renal
TRACERx Lung consortia
Pule, M
Marafioti, T
Gore, M
Larkin, J
Turajlic, S
Swanton, C
Peggs, KS
Quezada, SA
Type
Journal Article
Metadata
Show full item recordAbstract
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8<sup>+</sup> to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.
Collections
Licenseref URL
http://creativecommons.org/licenses/by/4.0/Version of record
Subject
TRACERx Melanoma
TRACERx Renal
TRACERx Lung consortia
Cell Line, Tumor
Animals
Humans
Mice
Melanoma
Receptors, IgG
Antibodies, Monoclonal
Treatment Outcome
Xenograft Model Antitumor Assays
Polymorphism, Single Nucleotide
Female
T-Lymphocytes, Regulatory
CTLA-4 Antigen
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Ipilimumab
Research team
Melanoma and Kidney Cancer
Sarcoma and Melanoma Surgery
Language
eng
Date accepted
2018-02-15
License start date
2018-04
Citation
Cancer cell, 2018, 33 (4), pp. 649 - 663.e4
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; Lesko, MH; Miranda Rota, E; Dahan, R; Georgiou, A; Sledzinska, A; Ben Aissa, A; Franz, D; Werner Sunderland, M; Wong, YNS; Henry, JY; O'Brien, T; Nicol, D; Challacombe, B; Beers, SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic, S; Gore, M; Larkin, J; Swanton, C; Chester, KA; Pule, M; Ravetch, JV; Marafioti, T; Peggs, KS; Quezada, SA (2017-04-11)CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ... -
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ... -
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani, M; Wilson, GA; McGranahan, N; Birkbak, NJ; Watkins, TBK; Veeriah, S; Shafi, S; Johnson, DH; Mitter, R; Rosenthal, R; Salm, M; Horswell, S; Escudero, M; Matthews, N; Rowan, A; Chambers, T; Moore, DA; Turajlic, S; Xu, H; Lee, S-M; Forster, MD; Ahmad, T; Hiley, CT; Abbosh, C; Falzon, M; Borg, E; Marafioti, T; Lawrence, D; Hayward, M; Kolvekar, S; Panagiotopoulos, N; Janes, SM; Thakrar, R; Ahmed, A; Blackhall, F; Summers, Y; Shah, R; Joseph, L; Quinn, AM; Crosbie, PA; Naidu, B; Middleton, G; Langman, G; Trotter, S; Nicolson, M; Remmen, H; Kerr, K; Chetty, M; Gomersall, L; Fennell, DA; Nakas, A; Rathinam, S; Anand, G; Khan, S; Russell, P; Ezhil, V; Ismail, B; Irvin-Sellers, M; Prakash, V; Lester, JF; Kornaszewska, M; Attanoos, R; Adams, H; Davies, H; Dentro, S; Taniere, P; O'Sullivan, B; Lowe, HL; Hartley, JA; Iles, N; Bell, H; Ngai, Y; Shaw, JA; Herrero, J; Szallasi, Z; Schwarz, RF; Stewart, A; Quezada, SA; Le Quesne, J; Van Loo, P; Dive, C; Hackshaw, A; Swanton, C; TRACERx Consortium (2017-06)<h4>Background</h4>Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate ...